Lipocine Announces Participation in Investment Conference
Lipocine Inc., a dedicated biopharmaceutical company focused on advancing its oral delivery technology, is set to present at the H.C. Wainwright 27th Annual Global Investment Conference. This exciting event is scheduled to take place on September 8-10, featuring both in-person and virtual attendance options for investors and industry stakeholders.
Management Presentation Details
During the conference, management will showcase Lipocine's innovative pipeline of drug candidates, providing insights into their potential impact on patients' quality of life. Investors can access the presentation starting from 7:00 a.m. EDT on the day of the conference. Those interested in engaging with Lipocine representatives for individual discussions are encouraged to coordinate through their H.C. Wainwright contact.
Innovative Drug Candidates in Development
Lipocine has a diverse portfolio of clinical candidates aimed at addressing significant healthcare needs. Its lead candidate, LPCN 1154, is an oral formulation of brexanolone designed for the treatment of postpartum depression. This innovative therapy represents a valuable option for patients experiencing this condition.
Additionally, LPCN 2101, targeting epilepsy management, and LPCN 2203, specifically developed for managing essential tremor, highlight Lipocine's commitment to improving treatment alternatives across various indications. The company is also advancing LPCN 2401, an anabolic androgen receptor agonist, and LPCN 1148, a prodrug aimed at liver cirrhosis management.
Strategic Partnerships and Collaborations
Lipocine recognizes the importance of collaboration and is actively pursuing partnership opportunities for many of its drug candidates. There is particular interest in LPCN 1107, a candidate aimed at preventing preterm birth, and LPCN 1154 for rapid postpartum depression treatment. By creating strategic alliances, Lipocine aims to optimize its development capabilities and extend the reach of its innovative therapies.
About Lipocine
Lipocine Inc. stands out in the biopharmaceutical field with its proprietary drug delivery system that enhances the oral absorption of various therapeutic compounds. The company's mission revolves around offering differentiated oral delivery options that can improve patient adherence and outcomes. Its candidate TLANDO has already received FDA approval for treating conditions related to low testosterone levels in adult males, demonstrating Lipocine's ability to navigate the regulatory landscape successfully.
For more information about Lipocine and its innovations, interested individuals can explore their official website for updates on the latest developments.
Frequently Asked Questions
What is the focus of Lipocine Inc.?
Lipocine Inc. is focused on developing innovative biopharmaceuticals that enhance oral drug delivery, particularly in areas with significant unmet medical needs.
When will Lipocine present at the H.C. Wainwright conference?
Lipocine will present from September 8-10, with available presentations starting at 7:00 a.m. EDT.
What are some key products in Lipocine's pipeline?
Key products include LPCN 1154 for postpartum depression, LPCN 2101 for epilepsy, and LPCN 2401 for obesity management, among others.
How can investors register for the conference?
Investors can register for the conference by contacting their H.C. Wainwright representatives or following event registration instructions.
What distinguishes Lipocine's approach to drug development?
Lipocine leverages proprietary technology to create patient-friendly oral drug delivery options that target large markets and address significant health issues.
